Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OK, thanks. I'm good, sitting on enough shares to make me happy, even though it would be a small number for you.
Perhaps Frost supplies the pixie dust and has the patents to protect it.
NR, That sounds good. Do you have any insight, thru your crystal ball, on a timeline? This CY vs next?
Having held Prolor, which was developing the ctp-enhanced compounds, I smile when I see one of their gems shine like this.
I smile when I see one of the gems from Prolor (acquired by OPK) shine like this.
NR, Thanks for sharing those reports.
That's a wise move, accumulating MNOV that way. Set a GTC order at the price you want to pay.
So you're up to 200 shares now? LOL
It looks as if Blackrock increased it's ownership last quarter, from 3.7 to 5.6 million shares.
Picked up a few shares during the day, FWIW. Can't pass up on a fire sale.
Al, I have little confidence in the management or negotiation skills of Zecotek management, but I'm along for the ride.
Zecotek Financial statements (unaudited):
http://www.zecotek.com/media/Zecotek%20Q3%20FS%20FY2015.pdf
Fierce Drug Delivery article about Ph 3 for CYNA
http://www.fiercedrugdelivery.com/story/cynapsus-sublingual-parkinsons-med-levodopa-nonresponders-progresses-phiii/2015-06-30?utm_medium=nl&utm_source=internal
Interesting point regarding possible merger between PGLC and Levon Resources:
"In February 2015, the Company earned a 9.9% interest in Pershing Gold Corporation (“Pershing Gold”) by acquiring 35,178,572 shares of common stock at USD $0.28 per share for an aggregate amount of USD $9,850,000. The purchase of shares of Pershing Gold represents the first step in a new Levon investment strategy to diversify its portfolio of assets. Pershing Gold's common stock is listed on the OTCQB under the symbol PGLC. On June 18,2015, Pershing Gold effected a reverse stock split at a ratio of 1-for-18, following which the Company holds 1,954,366shares, and now currently represents a 9.0% interest in Pershing Gold."
From:
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=140726
Cool. Looking forward to a great deal of progress, although I realize getting DRNE's house in order may not yet be complete.
I'm in. Just a small position in DRNE, but skin in the game. Long-time follower of Dr.Frost, and long: OPK, CDXC, COCP, PGLC and ROX. Was in PBTH, which Frost also controlled, and which was rolled up into OPK at a nice profit..
I like that article:
Fidelity shows my cost accurately.
HC, I've been in this perhaps too long term, but patiently holding.
HC, Well, let's hope Ashton will eventually exercise those options he was just granted. Sooner, rather than later.
Thanks for posting that George.
It went so smoothly I did not expect that small drop this morning. Must have been folks who didn't realize there was an offering OR some of the buyers in the offering are turning over some of their shares at a profit already.
Absolutely. A deal that sounds pretty good to me.
High, Not giving up on it yet.
033, If a brokerage holds stock for you and me and a thousand others in street name, let's say Fidelity, we count as just one holder. If I have Fidelity send me my share certificate (meaning I have complications if I want to sell), I count as one holder by myself. Hence the small number of holders.
Max, I'm sure you can multitask. Just stay long on ROX and don't screw up on the details of the house.
My wife used to sit in one bathroom with many different odd angles and report to me just what carpentry I had gotten "wrong."
The take on the IPO in Fierce Drug Delivery
1. Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma By Varun Saxena
"It's been a busy week on Wall Street for Parkinson's players all over the globe. Finland's Biotie Therapies ($BITI) saw its stock surge upon debut on the Nasdaq, Canada's Cynapsus plans to hit the exchange this week, and Israel's Intec Pharma plans to conduct an IPO shortly.
All three companies deploy drug delivery as one of their competitive advantages, demonstrating the therapeutic area's need for supplements, alternatives or improved versions of standard levodopa.
Biotie's share rose as high as $20.84 after debuting at $16.25 on Thursday. It originally priced 3.76 million shares at $14.88, so the IPO raised more than the planned for $56 million.
Its oral Parkinson's candidates apparently crosses the blood-brain barrier to block certain receptors that contribute toward Parkinson's symptoms like debilitating "off" episodes, during which patients have difficulty moving.
Lead candidate Tozadenant is preparing to enter Phase III trials. Biotie hopes it reduces the amount of time spent in off episodes when used in combination with the standard Parkinson's med levodopa, which suffers from variable absorption in the bloodstream, diminishes in effectiveness after about 5 years of use, and can cause dyskinesia (involuntary muscle movements).
Cynapsus hopes to raise $64 million by offering 4.5 million shares for $14.18, according to Renaissance Capital. It is currently listed on the Toronto Stock Exchange, where it has a market value of around $100 million.
The company expects to file a New Drug Application with the FDA in 2016 for its sublingual thin-film strip version of the second-line treatment apomorphine, for patients who don't respond adequately to levodopa/carbidopa.
Cynapsus promises to improve apomorphine therapy by eliminating the need for injections (offered by Britannia Pharmaceuticals under the name Apokyn), which can cause site reactions, and are difficult to administer among Parkinson's patients, who often lack dexterity.
In November, the company said 14 of the 16 Parkinson's disease patients responded positively to the candidate in its Phase II trial, and plans to complete three additional studies of bioavailability, efficacy and safety.
Finally, Intec Pharma aims to raise up to $46 million in a U.S. IPO, says Renaissance Capital. The company needs capital to deploy its levodopa-delivering Accordion Pill against Parkinson's in Phase III trials.
The Accordion Pill is meant to enhance delivery of drugs, such as levodopa, that have an absorption window limited to the upper part of the gastrointestinal tract. Intec hopes to prove that by releasing levodopa gradually, the Accordion Pill can increase its bioavailability and extend the absorption phase, thereby increasing the predictability and consistency of drug delivery into the bloodstream.
During in vivo drug delivery, the outer capsule of the Accordion pill dissolves in the stomach and the pill unfolds in an accordion-like manner, where it is retained for up to 12 hours. The drug is then continuously absorbed in the upper part of the GI tract."
It was a good annual report. I'm happy with the progress and hoping for some positive activity tomorrow.
Yes, Fun, It's your turn to drive the price up.
Max, We would really miss you. Now back to radio silence.
That is a good policy if you are standing on the ledge of a high-rise.
Zack's has an investment banking affiliate. If a company engages that affiliate for investment banking services, the odds of a positive recommendation from the other side of the chinese wall go up dramatically. When you no longer use the investment banking part, your recommendation might suddenly plummet.
Aw shucks. Maybe if we ALL travel we'll get a fantastic buyout offer. LOL
An interesting read.
http://www.eater.com/drinks/2015/6/9/8752465/inside-the-unsavory-world-of-counterfeit-whisky
Some day, Jeffersons will be counterfeited as well.
You are quite welcome!
I agree it is good progress, but I would like to see some prototype demonstrating the 2d/3d concept and then a big-time partner for the technology.
Next on my wish list ....
$1.65. More and more interesting. Fun, get your Depends on.
Definitely don't want to have much when you are operating machinery.
Just saw $1.62 now 1.61.
Congrats on scoring the Jeff's Groth!
Apollo, Thanks so much for linking us with great info. Much of it (scientific papers mostly) is over my pay grade but those slides were terriffic. You may want to post them here.
Apollo, Thanks, will check on the SYN presentation there.